Docetaxel and Irinotecan for Metastatic Gastric Cancer
Author Information
Author(s): Park S R, Chun J H, Yu M S, Lee J H, Ryu K W, Choi I J, Kim C G, Lee J S, Kim Y W, Bae J-M, Kim H K
Primary Institution: National Cancer Center
Hypothesis
Is the combination of docetaxel and irinotecan effective and safe for treating metastatic gastric cancer?
Conclusion
Weekly docetaxel and irinotecan is a promising outpatient regimen for metastatic gastric cancer with manageable toxicity.
Supporting Evidence
- The overall response rate was 45.7%.
- Median time to progression was 4.5 months.
- Median overall survival was 8.2 months.
- 57.4% of patients experienced grade 3/4 neutropenia.
Takeaway
This study tested a new treatment for stomach cancer using two drugs, and it worked well for many patients without causing too much harm.
Methodology
Patients received docetaxel and irinotecan every three weeks, and their responses were evaluated after treatment.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study had a small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
Median age was 56 years, with 59.2% males and 40.8% females.
Statistical Information
Confidence Interval
95% CI 31.3–60.1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website